Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies targeting ion channels in the central nervous system. The company's website is www.neuphoria.com.

Following the failure of its Phase 3 AFFIRM-1 trial for social anxiety disorder in October 2025, Neuphoria has significantly restructured its operations and is pursuing a proposed merger with Scancell Holdings plc, expected to close in late 2026. The company maintains clinical readiness of BNC210, its lead product candidate, for post-traumatic stress disorder treatment, though no active clinical trials are currently underway.

BNC210 is an oral, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor that has been evaluated in 15 clinical trials across multiple indications including generalized anxiety disorder, social anxiety disorder, and PTSD. The drug demonstrated a favorable safety profile without benzodiazepine-like side effects, sedation, or addiction potential in earlier studies. The Phase 2b ATTUNE trial in PTSD met its primary endpoint, and the FDA provided guidance on a potential registrational pathway involving one additional placebo-controlled trial and a 52-week open-label extension, though Neuphoria has not initiated this planned Phase 2b/3 SYMPHONY trial.

Beyond BNC210, Neuphoria maintains economic interests in several partnered programs. These include Merck's alpha7 positive allosteric modulator program for cognitive dysfunction, a KAT6 program licensed to Pfizer through the former Cancer Therapeutics Cooperative Research Centre, and Carina Biotech's LGR5-targeted CAR-T candidate for metastatic colorectal cancer. Neuphoria also retains legacy assets including BNC105, a vascular-disrupting agent previously evaluated in six clinical trials.

As of the fiscal year ended June 30, 2026, the company has substantially reduced its workforce to one full-time employee and terminated facility leases, relying on consulting arrangements and external support for essential functions. The company's current strategy focuses on completing the proposed merger with Scancell, preserving cash, maintaining public company obligations, and protecting the value of its partnered programs and intellectual property assets.